Top of this page
Skip navigation, go straight to the content

Our Company Key facts

Key facts

image description
  • A global biopharma focused on severe diseases in two therapeutic areas: neurology and immunology
  • Global revenue of € 4.5 billion in 2017
  • Operations in approximately 40 countries, supported by more than 7,500 people
  • Established in 1928, successful transformation from a hybrid specialty chemical company into a patient-centric biopharma company
  • Listed on the Euronext Brussels Stock Exchange
  • Headquartered in Brussels, Belgium.

Financials

Revenue - A 5-year overview

image description

Sales

Therapeutic areas

Focusing on severe diseases, UCB develops and markets human pharmaceutical products in two core therapeutic areas:

  • Neurology: epilepsy, Parkinson's disease, restless legs syndrome,...
  • Immunology: rheumatoid arthritis, Crohn's disease, lupus, bone health, psoriatic arthritis,...

Net sales 2017 - € 4,182 million

By therapeutic areas

image description

By geography

image description
 
 

Top selling products

€ million Actual
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017

Core products

Cimzia®594797108313071424
Vimpat®411471679814976
Keppra®712665737724778
Neupro®182200258302314
Briviact®   1887

Other products

Zyrtec® 204163147140103
Xyzal®11496117107104

Our people

Employees by region 2017

image description

Number of women vs men

image description
image description
 
image description